Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

ALLIANCE / A092105

Trial Overview

Official Title

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Advanced Nasopharyngeal Cancer

 

Study Purpose

To determine if progression-free survival is more favorable with triplet therapy combination of Cabozantinib + Nivolumab + Ipilimumab than with doublet therapy combination of Nivolumab + Ipilimumab

Diagnosis

Recurrent, metastatic and incurable Nasopharyngeal Carcinoma

Eligibility

1-2 prior lines of treatment with platinum-gemcitabine and PD-L1 blocker, with immunotherapy as part of the most recent treatment regimen

 

Intervention

Arm A:  Nivolumab + Ipilimumab.  Arm B:  Cabozantinib + Nivolumab + Ipilimumab.

For more information, click the link below:

 

https://clinicaltrials.gov/study/NCT05904080?term=A092105&rank=1

 

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center Methodist Jennie Edmundson Hospital
Gender
Male or Female
Age
18 years and Older
Enrollment Status
Recruiting
Phase
Phase II
Methodist Health System Trial Code
A092105